Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.61 USD
+0.02 (0.77%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.60 -0.01 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Allogene Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 449 | 517 | 457 | 828 | 531 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 10 | 12 | 14 | 17 | 14 |
Total Current Assets | 459 | 529 | 471 | 845 | 545 |
Net Property & Equipment | 99 | 113 | 123 | 119 | 56 |
Investments & Advances | 4 | 72 | 370 | 208 | 63 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 17 | 20 | 16 | 15 | 9 |
Total Assets | 643 | 817 | 1,039 | 1,228 | 718 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 14 | 10 | 10 | 9 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 31 | 40 | 38 | 45 | 24 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 0 | 39 | 0 |
Total Current Liabilities | 37 | 55 | 48 | 94 | 33 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 2 | 4 | 3 | 4 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 131 | 151 | 122 | 148 | 89 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,075 | 1,912 | 1,822 | 1,726 | 1,024 |
Retained Earnings | -1,562 | -1,236 | -903 | -646 | -396 |
Other Equity | -1 | -10 | -3 | 0 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 512 | 666 | 916 | 1,080 | 629 |
Total Liabilities & Shareholder's Equity | 643 | 817 | 1,039 | 1,228 | 718 |
Total Common Equity | 512 | 666 | 916 | 1,080 | 629 |
Shares Outstanding | 168.60 | 144.20 | 142.50 | 140.20 | 121.90 |
Book Value Per Share | 3.04 | 4.62 | 6.43 | 7.70 | 5.16 |
Fiscal Year End for Allogene Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 445 | 385 | 449 | 466 | 492 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 13 | 11 | 10 | 8 | 10 |
Total Current Assets | 457 | 395 | 459 | 473 | 502 |
Net Property & Equipment | 92 | 96 | 99 | 103 | 106 |
Investments & Advances | 1 | 15 | 4 | 38 | 63 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 38 | 15 | 17 | 20 | 20 |
Total Assets | 647 | 586 | 643 | 712 | 771 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 13 | 6 | 6 | 6 | 10 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 24 | 25 | 31 | 31 | 44 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 37 | 31 | 37 | 38 | 55 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 8 | 5 | 1 | 2 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 132 | 125 | 131 | 129 | 148 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,209 | 2,089 | 2,075 | 2,059 | 2,039 |
Retained Earnings | -1,694 | -1,627 | -1,562 | -1,474 | -1,413 |
Other Equity | -1 | -1 | -1 | -2 | -4 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 515 | 461 | 512 | 583 | 623 |
Total Liabilities & Shareholder's Equity | 647 | 586 | 643 | 712 | 771 |
Total Common Equity | 515 | 461 | 512 | 583 | 623 |
Shares Outstanding | 209.00 | 170.70 | 168.60 | 167.60 | 145.80 |
Book Value Per Share | 2.46 | 2.70 | 3.04 | 3.48 | 4.27 |